1. Home >
  2. M&A >
  3. Stake Purchase >
  4. Belgium >
  5. Boehringer Ingelheim Invests In SoundTalks NV

Investment Summary

Boehringer Ingelheim Invests In SoundTalks NV

On April 15, 2019, Boehringer Ingelheim invested in technology hardware company SoundTalks NV

Investment Highlights
  • This is Boehringer Ingelheim’s 1st transaction in the Technology Hardware sector.
  • This is Boehringer Ingelheim’s 1st transaction in Belgium.

Investment Summary
Date 2019-04-15
Target SoundTalks NV
Sector Technology Hardware
Investor(s) Boehringer Ingelheim
Deal Type Stake Purchase

Target

SoundTalks NV

Leuven, Belgium
SoundTalks NV is a Belgian technology-driven spin-off company that originated from the KU Leuven and the University of Milan in 2011. SoundTalks NV is committed to improving the health and welfare of livestock animals and the efficiency in the livestock production chain by delivering innovative automated monitoring solutions to the global market.

Search 214,557 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Boehringer Ingelheim

Ingelheim am Rhein, Germany
Category Company
Sector Healthcare Services
DESCRIPTION

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies.

DEAL STATS #
Overall 3 of 13
Sector: Technology Hardware M&A 1 of 1
Type: Stake Purchase M&A Deals 1 of 1
Country: Belgium M&A 1 of 2
Year: 2019 M&A 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-04 Malgrat Pharma Chemicals SLU

Barcelona, Spain

Malgrat Pharma Chemicals SLU has extensive experience in manufacturing cGMP (* 3) marketed synthetic pharmaceuticals as well as compounds in clinical development at different scales.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-15 AMAL Therapeutics SA

Geneve, Switzerland

AMAL Therapeutics SA is a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL Therapeutics is based in Geneve, Switzerland.

Buy €325M
Mergr

Solution for

Product

Company

Legal